Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: The utility of immunocytochemical panel in the differential diagnosis

Diagnostic Cytopathology

Volumn 37, Issue 5, 2009, Pages 324-332

  Saleh, Husain A ^a   El Fakharany, Mohammad ^a   Makki, Hassan ^b   Kadhim, Ahmad ^a   Masood, Shahla ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

Author keywords

BerEp4; Body fluids; Calretinin; CK5 6; D2 40; HBME 1; Immunocytochemical (ICC) stains; MOC 31; Monoclonal CEA; Serous effusion

Indexed keywords

CALRETININ; CARCINOEMBRYONIC ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BREAST ADENOCARCINOMA; CANCER DIAGNOSIS; CARCINOMA CELL; CELL DEGENERATION; CELL DIFFERENTIATION; CELL MATURATION; CELL MEMBRANE PERMEABILITY; CELL MOTION; CLINICAL ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTODIAGNOSIS; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EFFUSION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; LUNG ADENOCARCINOMA; MALE; MESOTHELIUM CELL; METASTASIS; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STAINING; STATISTICAL SIGNIFICANCE; STEM CELL; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; BODY FLUIDS; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL CELLS; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SENSITIVITY AND SPECIFICITY;

EID: 66349111493     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21006     Document Type: Article

References (47)

1. Ueda J, Iwata T, Ono M, Takahashi M. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion. Diagn Cytopathol 2006;34:6-10. (Pubitemid 43062697)
2. Butnor KJ. My approach to the diagnosis of mesothelial lesions. J Clin Pathol 2006;59:564-574. (Pubitemid 43886038)
3. Bedrossian CW. Diagnostic problems in serous effusions. Diagn Cytopathol 1998;19:131-137. (Pubitemid 28357785)
4. Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D. Cytologic malignancy versus benignancy: How useful are the "newer" markers in body fluid cytology? Arch Pathol Lab Med 2008;132:23-28.
5. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005;32:151-155. (Pubitemid 40256264)
6. Hecht JL, Pinkus JL, Pinkus GS. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations. Cancer 2006;108:56-59. (Pubitemid 43291245)
7. Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindan J. Immunocytochemistry in the differential diagnosis of serous effusions: A comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer 2001;93:68-72. (Pubitemid 32173189)
8. Morgan RL, De Young BR, McGaughy VR, Niemann TH. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer 1999;87:390-394. (Pubitemid 30016611)
9. Chhieng DC, Yee H, Schaefer D, et al. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions. Cancer 2000;90:194-200. (Pubitemid 30438953)
10. Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004;126:1757-1763. (Pubitemid 39643976)
11. Ko EC, Jhala NC, Shultz JJ, Chhieng DC. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. Am J Clin Pathol 2001;116:709-715. (Pubitemid 34453212)
12. Metzgeroth G, Kuhn C, Schultheis B, Hehlmann R, Hastka J. Diagnostic accuracy of cytology and immunocytology in carcinomatous effusions. Cytopathology 2007;19:205-211.
13. He DN, Zhu HS, Zhang KH, et al. E-cadherin and calretinin as immunocytochemical markers to differentiate malignant from benign serous effusions. World J Gastroenterol 2004;10:2406-2408. (Pubitemid 39157768)
14. Bhalla R, Siddiqui MT, Mandich D, et al. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks. Diagn Cytopathol 2007;35:342-347. (Pubitemid 46835024)
15. De Angelis M, Buley ID, Heryet A, Gray W. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4. Cytopathology 1992;3:111-117.
16. Delahaye M, van der Ham F, van der Kwast TH. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol 1997;17:115-120. (Pubitemid 27319129)
17. Athanassiadou P, Athanassiades P, Lazaris D, Kyrkou K, Petrakakou E, Aravantinos D. Immunocytochemical differentiation of reactive mesothelial cells and adenocarcinoma cells in serous effusions with the use of carcinoembryonic antigen and fibronectin. Acta Cytol 1994;38:718-722. (Pubitemid 24293417)
18. Pomjanski N, Grote HJ, Doganay P, Schmiemann V, Buckstegge B, Bocking A. Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Diagn Cytopathol 2005;33:309-315. (Pubitemid 41598050)
19. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynecological malignancies. Evaluation of five epithelial markers. Virchows Arch 1999;435:43-49.
20. Athanassiadou P, Gonidi M, Liossi A, et al. Moc-31, fibronectin and CEA in the differential diagnosis of malignant effusions: An immunocytochemical study. Pathol Oncol Res 2000;6:100-103. (Pubitemid 30646472)
21. Grefte JM, de Wilde PC, Salet-van de Pol MR, Tomassen M, Raaymakers- van Geloof WL, Bulten J. Improved identification of malignant cells in serous effusions using a small, robust panel of antibodies on paraffin-embedded cell suspensions. Acta Cytol 2008;52:35-44.
22. Daste G, Serre G, Mauduyt MA, Vincent C, Caveriviere P, Soleilhavoup JP. Immunophenotyping of mesothelial cells and carcinoma cells with monoclonal antibodies to cytokeratins, vimentin. CEA and EMA improves the cytodiagnosis of serous effusions. Cytopathology 1991;2:19-28.
23. Queiroz C, Barral-Netto M, Bacchi CE. Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry. Acta Cytol 2001;45:18-22.
24. Frisman DM, McCarthy WF, Schleiff P, Buckner SB, Nocito JD, Jr, O'Leary TJ. Immunocytochemistry in the differential diagnosis of effusions: Use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol 1993;6:179-184.
25. Gonzalez-Lois C, Ballestin C, Sotelo MT, Lopez-Rios F, Garcia- Prats MD, Villena V. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 2001;38:528-534. (Pubitemid 32863005)
26. Bailey ME, Brown RW, Mody DR, Cagle P, Ramzy I. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions: Comparison with carcinoembryonic antigen, B72.3 and Leu-M1. Acta Cytol 1996;40:1212-1216. (Pubitemid 26424475)
27. Ueda J, Iwata T, Takahashi M, Hoshii Y, Ishihara T. Comparative immunochemical study of lectin-binding sites and cytoskeletal filaments in static and reactive mesothelium and adenocarcinoma. Pathol Int 2001;51:431-439. (Pubitemid 32646208)
28. Szczepulska-Wojcik E, Langfort R, Roszkowski-Sliz K. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Pneumonol Alergol Pol 2007;75:57-69.
29. Fetsch PA, Simsir A, Abati A. Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology. Diagn Cytopathol 2001;25:158-161. (Pubitemid 32803830)
30. Ray K, Mittal S, Gupta H, Jain M. Cytological study of serous effusions with the aid of tumour markers. J Indian Med Assoc 1999;97:11-19.
31. Kitazume H, Kitamura K, Mukai K, et al. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: Utility of combined E-cadherin and calretinin immunostaining. Cancer 2000;90:55-60. (Pubitemid 30120289)
32. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: Stepwise logistic regression analysis. Cytopathol 2000;11:8-17. (Pubitemid 30106433)
33. Nagel H, Hemmerlein B, Ruschenburg I, Hüppe K, Droese M. The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelial versus metastatic tumors in effusion cytology. Pathol Res Pract 1998;194:759-764. (Pubitemid 28525921)
34. Afify AM, Al-Khafaji BM. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. Acta Cytol 2002;46:675-678. (Pubitemid 34787426)
35. Ghosh AK, Butler EB. Immunocytological staining reactions of anti-carcinoembryonic antigen, Ca, and anti-human milk fat globule monoclonal antibodies on benign and malignant exfoliated mesothelial cells. J Clin Pathol 1987;40:1424-1427. (Pubitemid 18026324)
36. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med 2005;129:1421-1427. (Pubitemid 41587017)
37. Kachali C, Eltoum I, Horton D, Chhieng DC. Use of mesothelin as a marker for mesothelial cells in cytologic specimens. Semin Diagn Pathol 2006;23:20-24. (Pubitemid 44415394)
38. Muller AM, Franke FE, Muller KM. D2-40: A reliable marker in the diagnosis of pleural mesothelioma. Pathobiology 2006;73:50-54. (Pubitemid 43952605)
39. Simsir A, Fetsch P, Abati A. Calretinin immunostaining in benign and malignant pleural effusions. Diagn Cytopathol 2001;24:149-152. (Pubitemid 32108527)
40. Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol 2006;30:878-882. (Pubitemid 44264979)
41. Wieczorek TJ, Krane JF. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations. Cancer 2000;90:312-319.
42. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: An update. Arch Pathol Lab Med 2005;129:1407-1414. (Pubitemid 41587015)
43. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: Identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006;19:514-523.
44. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: A comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-1051. (Pubitemid 36909525)
45. Zhu W, Michael CW. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 2007;35:370-375. (Pubitemid 46835030)
46. Gong Y, Sun X, Michael CW, Attal S, Williamson BA, Bedrossian CW. Immunocytochemistry of serous effusion specimens: A comparison of ThinPrep vs. cell block. Diagn Cytopathol 2003;28:1-5. (Pubitemid 36043475)
47. Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: A contemporary review. Cancer 2001;93:293-308. (Pubitemid 32995213)